Results 21 to 30 of about 10,116 (169)
orlistat improves release of gut hormones increasing satiety in obese women
Ожирение и метаболизм, 2014 Orlistat, which reduces fat absorption by inhibiting intestinal lipase is a registered drug for obesity pharmacotherapy. Meta-analyzes indicate various positive metabolic effects of orlistat, including improvements in glucose and lipid metabolism ...
Teona Albertovna Shvangiradze
doaj +1 more source
An Unexpected Result of Obesity Treatment: Orlistat-Related Acute Pancreatitis
Case Reports in Gastroenterology, 2015 Orlistat is a pancreatic lipase inhibitor which is used to treat obesity. Due to the increasing prevalence of obesity, orlistat use is thought to rise progressively. We report an interesting case caused by orlistat use caught in the early stages of acute
Murat Kose +6 more
doaj +1 more source
Future Journal of Pharmaceutical Sciences, 2021 Background Most of the analytical methods reported for the estimation of Orlistat were complex, expensive, and deficient in reproducibility with no or very less informative regarding various statistical methods and equations used for the validation ...
Kiran Singh Sharma, Jagannath Sahoo
doaj +1 more source
Nutrición HospitalariaOrlistat induces weight loss by blocking hydrolysis of triglyceride in the intestine, and has thereby been associated with favorable changes in postprandial triglycerides (ppTGL).
Ana Rodríguez-Valle +5 more
doaj +1 more source
Behavior of tetrahydrolipstatin in biological model membranes and emulsions
Journal of Lipid Research, 1997 Tetrahydrolipstatin (orlistat) (S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]methyl]dodecyl N-formyl-L-leucinate, a potent inhibitor of pancreatic lipase, is hydrophobic, amphipathic, and water-insoluble.
J Ko, D M Small
doaj +1 more source
Obesity, EarlyView.ABSTRACT Objective This study aimed to evaluate the trends in antiobesity medication (AOM) and metabolic and bariatric surgery (MBS) use relative to the 2013 American Medical Association (AMA) declaration of obesity as a chronic disease and semaglutide approval in 2021 in the United States.
Olajide A. Adekunle +7 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen +3 more
wiley +1 more source
Veterinary Sciences, 2021 Metabolic dysfunction-associated fatty liver disease (MAFLD) is an excessive buildup of liver lipids closely associated with various kinds of undesirable metabolic effects and oxidative stress.
Zaida Zakaria +5 more
doaj +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
The Application of Quantitative 1H-NMR for the Determination of Orlistat in Tablets
Molecules, 2017 A quantitative nuclear magnetic resonance (qNMR) method to measure the content of Orlistat in tablets was studied and found to be efficient, accurate, reliable, and simple.
Shanshan Sun +6 more
doaj +1 more source